Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 6/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mandelic Acid, Methyl Ester SCHEMBL28228867 | 1.00 | KMT2A (0.67) | KMT2ALMNAMAPK1CES2CES1 | |
| Mandelic Acid, Methyl Ester SCHEMBL186900 | 1.00 | KMT2A (0.67) | KMT2ALMNAMAPK1CES2CES1 | |
| Mandelic Acid, Methyl Ester SCHEMBL186899 | 1.00 | KMT2A (0.67) | KMT2ALMNAMAPK1CES2CES1 | |
| Mandelic Acid, Methyl Ester SCHEMBL7701656 | 0.98 | KMT2A (0.64) | KMT2ALMNAMAPK1CES2CES1 | |
| Mandelic Acid, Methyl Ester SCHEMBL27579970 | 0.98 | KMT2A (0.64) | KMT2ALMNAMAPK1CES2CES1 | |
| Mandelic Acid, Methyl Ester SCHEMBL8082961 | 0.98 | KMT2A (0.64) | KMT2ALMNAMAPK1CES2CES1 | |
| Mandelic Acid, Methyl Ester SCHEMBL7512539 | 0.96 | KMT2A (0.62) | KMT2ALMNAMAPK1CES2CES1 | |
| Mandelic Acid, Methyl Ester SCHEMBL29214409 | 0.94 | KMT2A (0.60) | KMT2ALMNAMAPK1CES2CES1 | |
| Mandelic Acid, Methyl Ester SCHEMBL30951860 | 0.92 | KMT2A (0.63) | KMT2ALMNAMAPK1CES2CES1 | |
| SCHEMBL6240606 | 0.92 | KMT2A (0.58) | KMT2ALMNAMAPK1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132118-A1 | SALT FORMS OF R-MDMA AND METHODS USING THE SAME | EMPATHBIO INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4642447-A2 | SALT FORMS OF R-MDMA AND METHODS USING THE SAME | EmpathBio, Inc. (US) | 2025-11-05 | — | — | EP | claimed |
| WO-2025125052-A1 | METHOD FOR ACTIVATING A HETEROGENEOUS CATALYST IN THE PRESENCE OF A MULTIFUNCTIONAL ACID COMPOUND | IFP Energies Nouvelles (FR) | 2025-06-19 | — | — | WO | claimed |
| CN-118702633-A | Preparation method of drug chlorinated intermediate for preventing cytomegalovirus infection | 台州职业技术学院 | 2024-09-27 | — | — | CN | claimed |
| CN-115583867-B | Resolution method of L-2-aminopropanol | 湖南复瑞生物医药技术有限责任公司 | 2024-08-02 | — | — | CN | claimed |
| US-20240217944-A1 | SALT FORMS OF R-MDMA AND METHODS USING THE SAME | EMPATHBIO, INC. | 2024-07-04 | — | — | US | claimed |
| WO-2024145663-A2 | SALT FORMS OF R-MDMA AND METHODS USING THE SAME | EMPATHBIO, INC. (US) | 2024-07-04 | — | — | WO | claimed |
| CN-118218027-A | Application of polydentate ligand/ruthenium catalyst and method for preparing diol compound by hydrogenation reaction of alpha-hydroxy ester | 郑州大学 | 2024-06-21 | — | — | CN | claimed |
| CN-113862117-B | Device and method for separating chiral substances by multi-liquid-phase system continuous enzyme method | 华南理工大学 | 2024-03-12 | — | — | CN | claimed |
| CN-114315866-B | Synthesis method of levamisole hydrochloride | 烟台药物研究所 | 2023-10-31 | — | — | CN | claimed |
| WO-1999048894-A1 | NOVEL CEPHALOTAXANE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | ONCOPHARM CORPORATION (US) | 1999-09-30 | — | — | WO | claimed |
| WO-1998022450-A1 | PROCESS FOR THE PREPARATION OF 2-IMINO-5-PHENYL-4-OXAZOLIDINONE AND ITS INTERMEDIATES | ABBOTT LABORATORIES (US) | 1998-05-28 | — | — | WO | claimed |
| US-5677463-A | Process for the preparation of 2-imino-5-phenyl-4 oxazolidinone and its intermediates | ABBOTT LABORATORIES (US) | 1997-10-14 | — | — | US | claimed |
| US-5332522-A | Thermotropic chiral nematic liquid crystalline copolymers | THE UNIVERSITY OF ROCHESTER (US) | 1994-07-26 | — | — | US | claimed |
| EP-0354068-B1 | Optically active piperazine derivative | NIPPON CHEMIPHAR CO (JP) | 1994-06-15 | — | — | EP | claimed |
| US-5243070-A | PROCESS FOR RESOLUTION OF RACEMATES OF 2,2-DIMETHYLCYCLOPROPANECARBOXYLIC ACID | LONZA LTD. (CH) | 1993-09-07 | — | — | US | claimed |
| EP-0342804-B1 | TRIOXANE COMPOSITION AND INSECT-PROOFING AGENT | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1992-12-02 | — | — | EP | claimed |
| US-5034493-A | Comprising the reaction product obtained by heating a mixture of a zinc carboxylate, a carboxylic anhydride aknd a phenol or glycidyl ether or ester; colorless; storage stability; fast c uring; optics | NEW JAPAN CHEMICAL CO., LTD. (JP) | 1991-07-23 | — | — | US | claimed |
| US-4973750-A | Preparation of (threo)-1-aryl-2-acylamido-3-fluoro-1-propanols | SCHERING CORPORATION (US) | 1990-11-27 | — | — | US | claimed |
| EP-0342804-A2 | Trioxane composition and insect-proofing agent | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1989-11-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217944-A1 | SALT FORMS OF R-MDMA AND METHODS USING THE SAME | SLC6A3, SLC6A4, SLC6A2 | KMT2A 576/4885LMNA 3044/4885MAPK1 941/4885 |
| US-20260132118-A1 | SALT FORMS OF R-MDMA AND METHODS USING THE SAME | SLC6A4, SLC6A3, SLC6A2 | KMT2A 873/4885LMNA 3572/4885MAPK1 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.